Skip to main content
ACTINOGEN MEDICAL LIMITED logo

ACTINOGEN MEDICAL LIMITED — Investor Relations & Filings

Ticker · ACW ISIN · AU000000ACW3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2026-05-20 Proxy Solicitation & In…
Country AU Australia
Listing ASX ACW

About ACTINOGEN MEDICAL LIMITED

https://actinogen.com.au/

Actinogen Medical Limited is a clinical-stage company focused on the development of novel therapies for neurological and metabolic diseases associated with chronically elevated cortisol. The company’s lead therapeutic candidate, Xanamem, is a small molecule designed to inhibit the 11β-HSD1 enzyme, which converts inactive cortisone to active cortisol within the brain and peripheral tissues. By reducing intracellular cortisol levels, Xanamem aims to address cognitive impairment and functional decline. The company’s primary clinical programs target Alzheimer’s disease and cognitive impairment associated with depression. Actinogen Medical Limited prioritizes the advancement of its lead candidate through rigorous clinical trials to establish efficacy in improving cognitive performance and managing stress-related neurological conditions.

Recent filings

Filing Released Lang Actions
Letter to Shareholders, Notice of GM & Proxy Form 37 pages 864.5KB
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a Notice of General Meeting and Explanatory Memorandum providing detailed meeting materials (agenda, resolutions, proxy instructions) for shareholder voting. It is a proxy solicitation/information statement rather than an earnings release, capital update, or general regulatory notice. Therefore it falls under Proxy Solicitation & Information Statement (PSI).
2026-05-20 English
Application for quotation of securities - ACW 7 pages 20.8KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX Appendix 2A form applying for quotation of 66,700,000 new ordinary shares issued under an employee incentive scheme. It is an announcement of a new share issue/capital change rather than a financial report, AGM material, earnings release, or regulatory certification. This falls squarely under the “Share Issue/Capital Change” category.
2026-05-20 English
Application for quotation of securities - ACW 6 pages 18.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX Appendix 2A application for quotation of additional securities following the exercise of options. It details the issuance of 35,098 new ordinary shares, issue price, and resulting issued capital. This is a clear announcement of a new share issue/capital change under ASX Listing Rules, fitting the Share Issue/Capital Change category.
2026-05-17 English
Application for quotation of securities - ACW 6 pages 18.2KB
Share Issue/Capital Change Classification · 93% confidence The document is an ASX Appendix 2A ‘Application for quotation of securities’ detailing the conversion of options into new ordinary shares, the number of securities issued, issue dates, consideration and updated issued capital. This is an announcement of a share issue/capital change. It is not a financial report, earnings release or AGM material, but a regulatory announcement of new securities. Therefore it should be classified as Share Issue/Capital Change (SHA).
2026-05-12 English
Appendix 3Y - Dr Steven Gourlay 2 pages 219.0KB
Director's Dealing Classification · 90% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice,” detailing the acquisition and disposal of securities by a company director. It reports personal share transactions by a director (insider trading disclosures). This matches the “Director's Dealing” category.
2026-05-12 English
ACW CEO options exercise and expiry reminder 3 pages 269.0KB
Director's Dealing Classification · 85% confidence The document is an ASX announcement detailing the Company’s CEO exercising unlisted options and reminding optionholders of upcoming expiries – i.e., a personal share transaction by a director. This fits the definition of an insider dealing report. Therefore, it should be classified as Director's Dealing (DIRS).
2026-05-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.